CHELMSFORD, Mass., May 16 /PRNewswire/ -- Magellan Biosciences, an emerging leader in clinical-diagnostics markets worldwide, will feature new automated systems designed to improve outcomes for busy microbiology labs at the American Society of Microbiology (ASM) meeting in Toronto, Canada. Magellan subsidiary, TREK Diagnostic Systems, will share booth 113 with sister company, Dynex Technologies, at the exhibition, which runs Tuesday through Thursday, May 22-24, 2007, at the Toronto Convention Centre.
TREK will launch its Vizion(TM) System, which adds digital-imaging capability to the company’s ARIS(R) 2X automated Sensititre(R) System with SWIN(R) (Sensititre for Windows(R)) software, to enable easy and accurate antimicrobial-resistance detection of all organism groups, including fastidious isolates that elude other automated systems. Dynex will feature its much-heralded DS2(TM) automated two-plate ELISA processing system. According to Magellan President and CEO, Robert J. Rosenthal, PhD, each platform demonstrates Magellan’s commitment to understanding customer needs and designing and building world-class products to serve them.
“Sensititre with SWIN is the system of choice for global surveillance programs because it is the only system that accommodates testing of the latest antimicrobial therapies in a single, accurate, and cost-effective platform - including routine and fastidious isolates, such as Haemophilus, Streptococcus, Mycobacteria, and yeast,” said Dr. Rosenthal. “Previously, susceptibility testing, particularly of fastidious organisms, was subject to interpretation of often difficult-to-read results. No more. TREK’s Vizion System enables surefire results through enhanced lighting options and on-screen display of large, easy-to-read digital images - with quantitative (Minimum Inhibitory Concentration) and qualitative results - color-coded to eliminate questionable readings and errors (red/resistant, yellow/intermediate, and green/susceptible). A touch-screen capability allows real-time recording of results, and Vizion is the only system that enables users to save and store images for sharing, teaching, and comparison. The SWIN controlling software, which incorporates the latest CLSI guidelines and epidemiology reporting capabilities, eradicates mistakes from manual data transcription - and laboratories can integrate the system directly into their existing laboratory information system (LIS) - to make reporting of results data easy.”
Dr. Rosenthal continued, “Dynex began shipments of the DS2 this month to ELISA kit manufacturers around the world to meet the needs of labs that don’t have the throughput needs to justify large-scale systems on the market. Designed with full walk-away capability, the DS2 represents a major leap forward in electro-mechanics and software design. Reliable, cost-effective, and easy to use and maintain, the DS2 packs full automation power in the smallest footprint available. The system quickly and easily processes two 96- well microplates and up to 12 different assays simultaneously and features the most user-friendly control system available, chain of custody, and instrument diagnostics. An open system, the DS2 delivers sample-in/results-out automation of virtually any ELISA microplate assay. Feature-rich and groundbreaking in its process simulation and ease of use, the DS-Matrix(TM) software allows any lab technician to use the DS2 with minimal training, so labs new to automation can rapidly integrate the system with confidence to begin delivering better, more-reliable results.”
About Magellan Biosciences
Magellan serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for hospital-based labs and near-patient testing. Scientists use the company’s discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness - from disease pathology to biomarker identification. Magellan designs all its systems, sensors, and consumables to deliver better, more-reliable results. And better results help drive improved health outcomes: earlier, more-accurate diagnoses; breakthroughs that can lead to novel treatments, new cures - innovations to enhance life. A privately held company, Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TREK Diagnostic Systems. For more information, visit www.magellanbio.com.
About TREK Diagnostic Systems
A Magellan Biosciences company and leader in automated systems and consumables for microbiology-based diagnostic testing, TREK serves the clinical, pharmaceutical, and veterinary markets. TREK’s VersaTREK(R) Automated Microbial Detection System and Sensititre(R) Automated Susceptibility and Identification Testing System, are designed to provide cost-effective improvements in workflow efficiencies, ergonomics, and results performance. For more information, visit www.trekds.com.
About Dynex Technologies
A Magellan Biosciences company, Dynex Technologies is the innovator in automated and semi-automated technologies for microplate analysis. From walk- away ELISA processing stations like its powerful, two-plate DS2 for low- throughput labs to the renowned four-plate DSX - Dynex designs each of its products to meet the rigorous demands of scientists in clinical, biomedical, and pharmaceutical-development applications. For more information, visit www.dynextechnologies.com.
Media Contact: Caroline Grossman, 781.771.5579, cgrossman@magellanbio.com
Magellan Biosciences
CONTACT: Caroline Grossman of Magellan Biosciences, +1-781-771-5579, orcgrossman@magellanbio.com
